newsfilter
← Latest News
Business Wire·

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

- Appointed Kate Hermans as Interim Chief Executive Officer – ​Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EP